Safety and Efficacy of Humanized Versus Murinized CD19 and CD22 CAR T-Cell Cocktail Therapy for Refractory/Relapsed B-Cell Lymphoma

Safety and Efficacy of Humanized Versus Murinized CD19 and CD22 CAR T-Cell Cocktail Therapy for Refractory/Relapsed B-Cell Lymphoma

CD19 chimeric antigen receptor T-cell (CAR-T) therapy is efficacious for refractory/relapsed (R/R) B-cell hematological malignancies, yet relapse due to CD19 antigen escape remains a challenge. Our trial explored simultaneous targeting of multiple B-cell antigens as a therapeutic approach that may r...

Full description

Bibliographic Details
Main Authors: Lefu Huang, Jingjing Li, Junfang Yang, Xian Zhang, Min Zhang, Jiujiang He, Gailing Zhang, Wenqian Li, Hui Wang, Jianqiang Li, Peihua Lu
Format: Article
Language:English
Published: MDPI AG 2022-12-01
Series:Cells
Subjects:
CAR-T
aggressive B-cell lymphoma
cocktail therapy
humanized
murinized
Online Access:https://www.mdpi.com/2073-4409/11/24/4085

Similar Items

Similar Items